Your dollar counts. Did you know most research foundations invest only a small percentage into actual research? 90% of WCRF donations go directly to research.

Your dollar counts. Did you know most research foundations invest only a small percentage into actual research? 90% of WCRF donations go directly to research.

Clinical Trials

RESULTING IN MORE EFFECTIVE TREATMENT

PIONEERS IN CLINICAL RESEARCH

Our research has resulted in more effective treatment modalities and cure rates that are higher than the national averages.

Since 1985, the WCRF physicians have been pioneers in clinical research to improve cure rates for women with ovarian, uterine, cervical and other gynecologic cancers.  

WCRF designs, conducts and publishes research on new leading edge medical treatments.

WCRF is not only conducting and publishing original research but is also a clearinghouse for information about the latest advancements in treating gynecologic cancers for physicians and patients.

Currently Open Trials

Protocol WCRF 452
Phase 1b/2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer (VIRO-15)

Protocol WCRF 453
A phase II trial evaluating the efficacy of Akynzeo in the management of chemotherapy induced nausea and vomiting in patients treated for advanced stage ovarian carcinoma

Protocol WCRF 454
A randomized , open-label, multicenter, phase 3 study to evaluate the efficacy and safety of AVELUMAB (MSB0010718C) in combination with and/or following chemotherapy in patients with previously untreated epithelial ovarian cancer

Protocol WCRF 455
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Protocol WCRF 456
A randomized multicenter Phase II trial to evaluate the safety, efficacy and immunogenicity of vaccination with Folate Receptor Alpha peptides admixed with GM-CSF as a vaccine adjuvant versus GM-CSF alone in patients with Platinum Sensitive Ovarian Cancer and a response or stable disease to platinum therapy

Recently COMPLETED

Protocol WCRF 451
An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator’s Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma

Protocol GOA-NVM1
A phase IV, randomized, double-blinded, multi-center study comparing the efficacy of Fosaprepitant with standard pre-medications to aprepitant with standard pre-medications for chemotherapy induced nausea and vomiting in patients treated for gynecological cancer

Protocol GOG-0261
A randomized phase III trial of Paclitaxel plus Carboplatin versus Ifosfamide plus Paclitaxel in chemotherapy-naive patients with newly diagnosed stage I-V persistent or recurrent carcinosarcoma (mixed mesodermal tumors) of the uterus, fallopian tube, peritoneum  or ovary

Protocol GOG-186
A randomized Phase IIB evaluation of weekly Paclitaxel (NSC #673089) plus Pazopanib (NSC #737754) (IND #75648) versus weekly Paclitaxel plus placebo in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma

Protocol GOG-0241
A GCIG intergroup multicenter phase III trial of open label Carboplatin and Paclitaxel +/- NCI-supplied agent: Bevacizumab (NSC #704865, IND #113912) compared with Oxaliplatin and Capecitabine +/- Bevacizumab as first line chemotherapy in patients with mucinous epithelial ovarian or fallopian tube cancer (MEOC)

Protocol GOG-0258
A randomized phase III trial of Cisplatin and tumor volume directed irradiation followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for optimally debulked, advanced endometrial carcinoma

Protocol 08-PIR-04
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer.  .

Protocol GOA-TCOV
A Phase I/II, Open-Label, Non-Randomized, Pilot Study of weekly Paclitaxel, every four-week Carboplatin and Oral Vorinostat for Patients Newly Diagnosed with Stage III/IV Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Protocol 3144A2-3004-WW
A Randomized Double-Blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early HER-2/neu Overexpressed/ Amplified Breast Cancer

Protocol XL147-201
A Phase 2 Study of XL147 in subjects with advanced or recurrent endometrial carcinoma

Protocol GOAWP3C
A Phase II, open-label, non-randomized, multi-center study of weekly Paclitaxel and every 3 week Carboplatin for treatment of primary epithelial ovarian, fallopian tube, peritoneal or malignant peritoneal mesothelioma

Protocol SHH4489g  -01/2011
A phase II multicenter, randomized, double blind, placebo controlled trial evaluating the efficacy and safety of GDC-0449 as maintenance therapy in patients with ovarian cancer in a second or third complete

Protocol DOXILOVC2007 -01/2011
A Phase II Single Arm Study of Carboplatin and DOXIL® plus Bevacizumab in Subjects with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Protocol EC-FV-04 -10/2010
A randomized phase II trial comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil/Caelyx) in combination versus PLD alone in subjects with paltinum resistant ovarian cancer

Protocol MORAb-003-004 -8/2010
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First Relapse

Protocol M10-747  -9/1/2010
A Phase 2 Randomized clinical Trial of ABT-888 in Combination with Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Subjects with Recurrent High Grade Serious Ovarian Cancer

Protocol 20060342   -2010
A randomized, double-blind, placebo controlled phase 2 trial of paclitaxel in combination with AMG 386 in subjects with advanced recurrent epithelial ovarian or primary peritoneal cancer.

Protocol SPO-0010  -2010
A phase 2 open-label, multicenter study of SNS‑595 injection in patients with platinum-resistant ovarian cancer

Protocol AVF4095g  -2010
A phase II, multicenter, randomized, blinded, placebo-controlled trial of Carboplatin and Gemcitabine plus Bevacizumab in patients with platinum‑sensitive recurrent ovary, primary peritoneal, or fallopian tube carcinoma.

Protocol AVF4121s
A phase II, open-label, non-randomized, pilot study of weekly paclitaxel and every four-week carboplatin with bevacizumab given every two weeks for patients newly diagnosed with stage III/IV epithelial ovarian, fallopian tube or peritoneal cancer.

Protocol AVF3206s
A Phase II, open-label, non-randomized, multi-center pilot study of Intravenous Taxol, Carboplatin, and Bevacizumab (Avastin) given every 21 days in patients with newly diagnosed stage III/IV epithelial ovarian, fallopian tube, or peritoneal cancer.

Protocol Perifosine 207
A Phase IIA trial of two schedules of Perifosine in patients for whom no standard therapy exists.

Protocol Perifosine 211
A randomized placebo controlled study of Perifosine in combination with single agent chemotherapy for second-line metastatic cancer patients.

Protocol PXD101-CLN-8
A phase I safety, pharmacodynamic, and pharmacokinetic study of intravenously administered PXD101 plus Carboplatin or Paclitaxel or both in patients with advanced solid tumours.

Protocol EC-FV-02
A phase II study of EC 145 in patients with advanced ovarian and endometrial cancers.

Blue Button with an Accessibility icon and it reads Accessible